Future Medicine Co., Ltd.
KKRX:34117030.00
KRW
-2.00
(-6.25%)
ISIN
KR7341170009
Return %
Stock
S&P 500
1Y
-98.00
13.14
3Y
-99.61
80.78
5Y
- -
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 4
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seongnam-si South Korea
- IPO Date
- Jul 27, 2022
- Website
- futuremedicine.co.kr
- Similar Companies
- Business
- Future Medicine Co., Ltd. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule therapeutics and nucleoside-derived compounds for the treatment of fibrotic, inflammatory, oncological, metabolic, and viral diseases. Founded in 2014 and headquartered in Seoul, South Korea, the company operates dedicated research and development facilities in South Korea and engages in preclinical and clinical programs across Asia, North America, and Europe. Future Medicine specializes in targeted medicinal chemistry and nucleoside modification to address severe unmet medical conditions worldwide. The company's core product pipeline and service offerings include FM101, a selective A3 adenosine receptor (A3AR) antagonist under clinical evaluation for metabolic dysfunction-associated steatohepatitis (MASH/NASH), primary sclerosing cholangitis (PSC), liver fibrosis, and ophthalmic conditions such as wet age-related macular degeneration (AMD) and glaucoma; FM201, an oral targeted oncology candidate developed for acute myeloid leukemia (AML) and various solid tumors; FM301, an anti-fibrotic therapeutic candidate for chronic kidney disease and pulmonary fibrosis; FM401, a broad-spectrum nucleoside-based antiviral candidate targeting RNA viral infections; FM501, a small-molecule drug candidate for autoimmune and metabolic disorders; the proprietary FOCUS (Future Optimized Chemical Unique Structure) nucleoside drug discovery platform, which provides targeted medicinal chemistry design, preclinical screening, lead optimization, and intellectual property licensing services to biopharmaceutical collaborators; and nucleoside-derived functional bio-ingredients and cosmeceutical formulations developed for dermatological health and anti-aging applications. In recent developments, Future Medicine has advanced global clinical trial programs for its lead asset FM101 across hepatic and ophthalmic indications, entered into strategic collaborative research and out-licensing discussions with multinational pharmaceutical partners, and established co-development agreements with specialized contract development and manufacturing organizations (CDMOs). The company has also expanded multinational patent protections across major jurisdictions for its core A3AR antagonist and antiviral candidates, advanced preparations for a transfer listing from the Korea New Exchange (KONEX) to the KOSDAQ market, and broadened its commercial strategy through pipeline extensions into dermatology and metabolic health products.